Vergence Naturals and Naturopathic Doctor and Nutraceutical Product Developer Brazos Minshew Launch Comfort
VANCOUVER, British Columbia, Dec. 18, 2018 /PRNewswire/ -- Abattis Bioceuticals Corp (the "Company" or "Abattis") (CSE:ATT) (OTC:ATTBF) is pleased to announce its first proprietary product, Comfort, which has been produced through wholly owned subsidiary Vergence Naturals ("Vergence"). Abattis has teamed up with respected naturopathic doctor and nutraceuticals product developer Dr. Brazos Minshew to launch Comfort, a breakthrough nutraceutical combining traditional herbal remedies to safely and effectively address occasional pain. Released on Cyber Monday and set for introduction into the US and Canada in December 2018, the Comfort product is 100% owned by Vergence, and will be marketed under the newly-formed health and wellness brand. Comfort offers a unique combination of phytocannabinoids from non-cannabis sources to safely and effectively address occasional pain. Dr. Minshew currently serves as President of Abattis' Medical Advisory Board.
For thousands of years plants have been used in medicine to reduce occasional pain. For example, Aspirin is derived from White Willow Bark, and morphine is derived from plants in the poppy species. Following this trend, cannabinoids from marijuana have been used by progressive physicians to successfully treat pain. Scientists have identified cannabinoids in many non-cannabis plants, such as hops, turmeric and cocoa which yield full-functional health benefits. Comfort by Vergence (www.comfortbyvergence.com) uniquely blends five non-cannabis plants used to reduce occasional pain by interacting with cannabis receptors in the brain without any cannabis side effects.
Dr. Minshew and Abattis successfully combined five phytocannabinoids to create Comfort, including:
- Turmeric phytocannabinoids and terpenes to support a healthy inflammatory response without the side effects of cannabis. Curcumin from turmeric powerfully activates cannabis receptors for relief of occasional pain. 1
- Ginger phytocannabinoids and terpenes to support a healthy COX-2 inflammatory response, balance leukotrienes and quiet certain genes associated with pain.2
- Kaemfera galangal phytocannabinoids and terpenes to inhibit pain from multiple pathways, including histamine, serotonin and bradykinin induced pain models.3
- Frankincense phytocannabinoids and terpenes to strongly inhibit occasional pain that arises from the nervous system itself (neuropathic pain). This is important because, over time, the brain pathways related to occasional pain tend to experience pain even when nothing is really wrong.4
- Red pepper phytocannabinoids and terpenes harmonize and amplify the cannabinoids of other plants. Further, pain is often worsened by obesity and obesity, in turn, may produce sensitivity to pain. Red Pepper reduces the pain process that is directly associated with obesity.5
"I am excited to join with Abattis Bioceuticals Corp. in the development and launch of Comfort and to establish Vergence as a new and innovative health-wellness manufacturing brand. Comfort uniquely blends phytocannabinoids from non-cannabis plant species to deliver safe and effective relief from occasional pain. We look forward to introducing this extraordinary remedy to adults throughout North America," said Dr. Minshew.
"Dr. Brazos Minshew has worked tirelessly throughout his distinguished career in medicine to create herbal remedies focusing on endocannabinoid and phytocannabinoid science. Comfort is the result of Dr. Minshew's intense experience in this critically important area of wellness and we are proud to work together to introduce his latest achievement to the public," said Abattis CEO, Rob Abenante.
Dr. Brazos has dedicated his professional life to the development of wellness technologies that promote health and prolong vitality. His cutting-edge work in bioscience has led to the creation of life-enhancing therapies and helped expand the knowledge and understanding of Functional Medicine. He ranks among the most respected product developers in the burgeoning field of nutraceuticals. Dr. Minshew graduated from Hollywood College in 1981 with a degree in Naturopathy, from University of California, Los Angeles (UCLA) in 1985 in Psychophysiology, from Brantridge Forrest School in 1987 as a Doctor of Naturopathic Medicine, and from Brantridge University in 1993 with a Master of Science degree in Acupuncture and Oriental Medicine. He has been in clinical practice for more than 35 years. Dr. Minshew has significant experience in creating formal and ad hoc medical advisory boards and scientific panels in support of Wellness initiatives worldwide. As a media contributor, Dr. Minshew has prepared over 250 Weekly Wellness Reports for 320,000 subscribers, as well as more than 180 VitaJournal articles with circulations exceeding 450,000 and produced a series of audiobooks including the acclaimed Body Systems 101. At the same time, his collection of YouTube videos on health and wellness have achieved thousands of visitors. As a speaker, Dr. Minshew's travels have taken across the United States, Canada, Latin America, Europe and Asia, and averages more than 60 speaking engagements each year.
About Abattis Bioceuticals Corp.
Abattis is a life sciences and biotechnology company which aggregates, integrates, and invests in cannabis technologies and biotechnology services for the legal cannabis industry developing in Canada. The Company has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biological, nutraceutical, bioceutical, and cosmetic markets. The Company is also seeking to acquire exclusive intellectual property rights to agricultural technologies to be employed in extraction and processing of botanical ingredients and compounds. The Company follows strict standard operating protocols and adheres to applicable laws of Canada and foreign jurisdictions. Abattis has not conducted any scientific studies on the effects of Abattis' products which have been evaluated by Health Canada or the U.S. Food and Drug Administration. As each individual is different, the benefits, if any, of taking Abattis' products will vary from person to person. No claims or guarantees can be made as to the effects of Abattis' products on an individual's health and wellbeing.
ON BEHALF OF ABATTIS BIOCEUTICALS CORP,
"Rob Abenante"
Robert Abenante, President & CEO
For more information, please visit the Company's website at: www.abattis.com
For inquiries please contact (808) 650-3007 or at [email protected]. Abattis' investor relations are managed by Canada One Communications Inc.
About Canada One Communications Inc.
Canada One Communications Inc. ("Canada One") is a full-service Investor Relations and Marketing company that focuses on both private and public sectors within the Canadian markets. Canada One offers timely responses to all investor inquiries over several mediums and effective, thorough market awareness programs that are specifically designed to maximize exposure and bring value to shareholders. Canada One's dedicated and experienced team strives to promote client information to the public and educate potential investors on the various developments of its clients. From basic phone-call and email investor correspondence, to full-scale comprehensive marketing packages which includes industry analysis, website development, corporate videos and other marketing programs, Canada One provides a full suite of services that are fully compliant with Canadian securities regulations. Canada One is driven by an uncompromising dedication to provide publicly listed and private companies with across-the-board investor relations and marketing solutions, directly translating these services into organic growth and increased market value of its valued clients.
References
1. Altern Med Rev. 2009 Jun;14(2):141-53. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Jurenka JS1.
3. http://www.cysonline.org/temp/ChronYoungSci23139-6969308_192133.pdf
4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5736925/
5. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5442453/
6. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333598/
7. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3691841/
FORWARD LOOKING INFORMATION
This press release contains forward-looking statements. The use of any of the words including but not exclusive to "anticipate", "continue", "estimate", "expect", "may", "will", "project", "intends", "should", "believe" and similar expressions are intended to identify forward-looking statements. Forward-looking statements in this press release include statements regarding the timing for release of Comfort by Vergence and the cannabinoid-infused nutraceutical market in general. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Additional risk factors are included in the Company's Management's Discussion and Analysis, available under the Company's profile on www.sedar.com. The forward-looking statements are made as at the date hereof and the Company disclaims any intent or obligation to publicly update any forward-looking statements, where because of new information, future events or results, or otherwise, except as required by applicable securities laws. Abattis has not conducted any scientific studies on the effects of Abattis' products which have been evaluated by Health Canada or the U.S. Food and Drug Administration. As each individual is different, the benefits, if any, of taking Abattis' products will vary from person to person. No claims or guarantees can be made as to the effects of Abattis' products on an individual's health and wellbeing.
SOURCE Abattis Bioceuticals Corp.
Share this article